---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060673"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:00:27.783827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports Q3 net loss of $39.2M; cash runway extends to H2 2026

## Summary
- Cash and investments $481.9M at Sept 30, 2023; runway extended into H2 2026 from prior into 2026, driven by $38M ATM net proceeds and higher interest income.
- Net loss $39.2M in Q3 vs $32.2M in Q2; R&D expenses $33.8M (up from $27.4M) on higher manufacturing and clinical costs.
- CLN-619 (MICA/B) monotherapy clinical activity observed; combination dose escalation enrollment completed; initial data expected Q2 2024.
- Zipalertinib (EGFR ex20ins) Phase 2b REZILIENT1 enrollment completion targeted by end 2024; Phase 3 REZILIENT3 initiated.
- CLN-978 (CD19xCD3) first patient dosed in Phase 1 for R/R B-NHL; CLN-617 first-in-human expected by year-end 2023.

## SEC filing metadata
- accession: 0000950170-23-060673
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/0000950170-23-060673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/cgem-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060673
- JSON: https://secwatch.observer/filing/0000950170-23-060673.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060673.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. updated its third quarter ended September 30, 2023 guidance (reaffirmed).
  - Period: third quarter ended September 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/0000950170-23-060673-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.